Evidence map›Paper›PMID 35893702›Full record

Observational studyViruses2022

Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic.

Chi-Ming Tai, Chun-Kai Huang, Te-Chang Changchien, Po-Chun Lin, Deng-Wu Wang, Ting-Ting Chang, Hsue-Wei Chan, Tzu-Haw Chen, Cheng-Hao Tseng, Chih-Cheng Chen and 4 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Chi-Ming TaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 84001, Taiwan.ORCID 0000-0002-1605-3516
Chun-Kai HuangDivision of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 84001, Taiwan.
Te-Chang ChangchienSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Po-Chun LinSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Deng-Wu WangSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Ting-Ting ChangSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Hsue-Wei ChanSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Tzu-Haw ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 84001, Taiwan.
Cheng-Hao TsengSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Chih-Cheng ChenSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Chia-Ta TsaiDivision of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 84001, Taiwan.
Yu-Ting SieSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Yung-Chieh YenSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
Ming-Lung YuHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.ORCID 0000-0001-8145-1900
E-Da Hospital · TWI-Shou University · TWNational Sun Yat-sen University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although hepatitis C virus (HCV) prevails in patients receiving methadone maintenance treatment (MMT), most do not receive anti-HCV therapy. This single-center observational study aimed to achieve HCV micro-elimination at an MMT center during the COVID-19 pandemic using a collaborative referral model, which comprised a referral-for-diagnosis stage (January 2020 to August 2020) and an on-site-diagnosis stage (September 2020 to January 2021). A multidisciplinary team was established and all MMT center patients were enrolled. HCV micro-elimination was defined as >90% of HCV-infected patients diagnosed and >80% of HCV-viremic patients treated. A total of 305 MMT patients, including 275 (90.2%) anti-HCV seropositive patients, were enrolled. Among 189 HCV-infected patients needing referral, the accumulative percentage receiving HCV RNA testing increased from 93 (49.2%) at referral-for-diagnosis stage to 168 (88.9%) at on-site-diagnosis stage. Among 138 HCV-viremic patients, the accumulative percentage receiving direct-acting antiviral (DAA) therapy increased from 77 (55.8%) at referral-for-diagnosis stage to 129 (93.5%) at on-site-diagnosis stage. We achieved an HCV RNA testing rate of 92.4% (254/275), an HCV treatment rate of 95.8% (203/212) and a sustained virological response rate of 94.1% (191/203). The collaborative referral model is highly effective in HCV RNA testing and HCV treatment uptake among MMT patients, achieving HCV micro-elimination.

Indexed as

COVID-19COVID-19 Drug TreatmentHepatitis CHepatitis C, ChronicAntiviral AgentsHepacivirusHumansMethadonePandemicsReferral and ConsultationRNAAntiviral AgentsMethadoneRNACOVID-19direct-acting antiviral agenthepacivirushepatitis Cmethadone maintenance treatmentpeople who inject drugs

Identifiers

PMID35893702
PMCPMC9332799
OpenAlexW4288177659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.